What are the benefits of the ExoDx Prostate IntelliScore (EPI CE-IVD)?
The EPI-CE test provides a risk assessment for finding clinically significant prostate cancer that otherwise relies on biopsy in men with an elevated PSA. Right now, there just isn’t great information that can help doctors and patients screen for and diagnose prostate cancer without the over-reliance on prostate biopsies. The EPI-CE test provides a simple, painless, and accurate answer to inform the prostate biopsy decision. If the test result indicates that a “low risk”, then the man and his doctor (using all other clinical information including family history, prior PSA, abnormal DRE) may decide to defer prostate biopsy – avoiding the pain, complications and costs associated with a prostate biopsy.
Should I Get The EPI-CE Test?
If you are a man over the age of 50 with a prostate specific antigen (PSA) of 2-10 ng/mL, have not had an MRI and are considering a prostate biopsy, then you should talk to your doctor or health care provider about the EPI-CE test.
The EPI-CE test helps physicians and patients make critical decisions about whether or not to proceed to or defer prostate biopsy.
The EPI-CE test:
- Simple, non-invasive urine test
- Based on the U.S. EPI test which has been performed successfully for more than 60,000 men since 2016 in the ExosomeDx CLIA lab, and is included in the May 2019 NCCN guidelines
- Proven to avoid almost 34% of potentially unnecessary biopsies